CytomX Therapeutics, Inc. (CTMX) Insider Sells $163,215.26 in Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) insider Sean A. Mccarthy sold 6,526 shares of the stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $25.01, for a total value of $163,215.26. Following the completion of the transaction, the insider now directly owns 11,169 shares of the company’s stock, valued at $279,336.69. The sale was disclosed in a filing with the SEC, which is available at this link.

CytomX Therapeutics, Inc. (NASDAQ CTMX) traded down $0.53 during mid-day trading on Tuesday, reaching $24.34. The company had a trading volume of 634,500 shares, compared to its average volume of 427,780. CytomX Therapeutics, Inc. has a 12-month low of $10.64 and a 12-month high of $25.21. The firm has a market cap of $961.75 and a PE ratio of -15.50.

A number of brokerages have recently issued reports on CTMX. Cowen reissued an “outperform” rating on shares of CytomX Therapeutics in a report on Thursday, October 5th. Citigroup began coverage on CytomX Therapeutics in a report on Friday. They issued a “buy” rating and a $40.00 target price for the company. BidaskClub raised CytomX Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, December 15th. ValuEngine cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, Zacks Investment Research raised CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a report on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $32.78.

A number of hedge funds have recently added to or reduced their stakes in CTMX. Russell Investments Group Ltd. boosted its position in CytomX Therapeutics by 1.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 22,134 shares of the biotechnology company’s stock valued at $343,000 after buying an additional 292 shares during the last quarter. Legal & General Group Plc boosted its position in CytomX Therapeutics by 28.6% in the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 1,434 shares during the last quarter. Nationwide Fund Advisors boosted its position in CytomX Therapeutics by 39.4% in the 2nd quarter. Nationwide Fund Advisors now owns 16,365 shares of the biotechnology company’s stock valued at $254,000 after buying an additional 4,622 shares during the last quarter. New York State Common Retirement Fund boosted its position in CytomX Therapeutics by 18.6% in the 3rd quarter. New York State Common Retirement Fund now owns 36,900 shares of the biotechnology company’s stock valued at $670,000 after buying an additional 5,800 shares during the last quarter. Finally, Macquarie Group Ltd. bought a new position in CytomX Therapeutics in the 3rd quarter valued at $107,000. 63.13% of the stock is owned by hedge funds and other institutional investors.

WARNING: This piece was posted by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://www.com-unik.info/2018/01/09/cytomx-therapeutics-inc-ctmx-insider-sells-163215-26-in-stock.html.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit